Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
[225ac]-fpi-2068 Head And Neck Squamous Cell Carcinoma	AstraZeneca	P1	C (37)
[225ac]-fpi-2068 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (37)
[225ac]-fpi-2068 Renal Cell Carcinoma	AstraZeneca	P1	C (37)
Autologous, Engineered T Cells Targeting Tp53 R175H Head And Neck Squamous Cell Carcinoma	AstraZeneca	P1	C (37)
azd0120 Multiple Sclerosis	AstraZeneca	P1	C (37)
AZD0240 Endometrial Carcinoma	AstraZeneca	P1	C (37)
AZD0240 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (37)
AZD0240 Solid Tumor, Adult	AstraZeneca	P1	C (37)
azd0240: autologous, engineered t cells targeting kras g12d Endometrial Carcinoma	AstraZeneca	P1	C (37)
azd0240: autologous, engineered t cells targeting kras g12d Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (37)
azd0240: autologous, engineered t cells targeting kras g12d Solid Tumor, Adult	AstraZeneca	P1	C (37)
azd2275 Metastatic Prostate Carcinoma	AstraZeneca	P1	C (37)
azd2284 Metastatic Prostate Carcinoma	AstraZeneca	P1	C (37)
azd5335 Fallopian Tube Cancer	AstraZeneca	P1	C (37)
Fpi-2053 Gastric Cancer	AstraZeneca	P1	C (37)
Fpi-2053 Head And Neck Squamous Cell Carcinoma	AstraZeneca	P1	C (37)
Fpi-2053 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (37)
Fpi-2053 Renal Cell Carcinoma	AstraZeneca	P1	C (37)
Itraconazole Fallopian Tube Cancer	AstraZeneca	P1	C (37)
NT-112 Endometrial Carcinoma	AstraZeneca	P1	C (37)
NT-112 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (37)
NT-112 Solid Tumor, Adult	AstraZeneca	P1	C (37)
[111in]-fpi-2107 Cancer	AstraZeneca	P1	C (36)
[225ac]-fpi-2068 Cancer	AstraZeneca	P1	C (36)
[225ac]-fpi-2068 Non-Small Cell Lung Carcinoma	AstraZeneca	P1	C (36)

Showing 426 to 450 of 502 assets

PreviousPage 18 of 21Next